ArticleClinical kidney journal2026
Treatment response to daratumumab in antibody-mediated kidney allograft rejection: evidence from serial protocol biopsies.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-mediated rejection (ABMR) is a major cause of chronic allograft dysfunction and graft loss after kidney transplantation (KTx). Daratumumab, antibody targeting the transmembrane glycoprotein CD38 (cluster of differentiation) on immune cells, has shown promise in the treatment of refractory ABMR in adult solid organ transplantation; however, pediatric data are scarce. Methods: We report two pediatric cases of refractory ABMR after KTx treated with daratumumab with followed-up protocol biopsies over 10-12 months. Treatment consisted of an induction phase with five weekly doses followed by maintenance dosing every two to four weeks. Donor-specific antibodies (DSAs), kidney function, albuminuria, and histologic response were assessed. Results: The first case, a 10-year-old girl with recurrent ABMR after KTx showed histologic improvement from active ABMR with C4d positivity, glomerulitis, and severe microvascular inflammation to predominantly chronic changes without signs of active rejection. Microvascular inflammation became mild and C4d staining turned negative. The second case, a 9-year-old boy with active and chronic antiglomerular basement membrane disease and severe transplant ABMR glomerulopathy initially showed progression of chronic injury, followed by complete histologic resolution of active disease, disappearance of C4d staining, minimal fibrosis (<1%), and marked reduction of albuminuria after 10 months. Both patients demonstrated reduced DSA levels, stabilization of graft function, and no serious adverse events. Conclusion: Daratumumab was associated with histologic improvement, reduction of microvascular inflammation, and stabilization of graft function in two children with refractory ABMR after KTx. Controlled studies to determine the safety, efficacy, and optimal dosage of daratumumab in children with ABMR are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.